Planet Labs (PL) Is Up 6.6% After European Agri-Data Deal And Pelican First Light Milestone

• Planet Labs PBC recently released first light images from three newly launched Pelican satellites, including the Swedish Armed Forces’ first sovereign satellite, and its Sinergise subsidiary secured a 2-year, 7-figure contract to supply satellite imagery and AI analytics for Czech agricultural monitoring.
• Together, these developments highlight Planet’s progress in pairing an expanding, AI-enabled high-resolution constellation with recurring government and agriculture data contracts across Europe.
• We’ll now examine how this new European agriculture contract, alongside the Pelican first light milestone, reshapes Planet Labs’ investment narrative.

We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Planet Labs PBC Investment Narrative Recap

To own Planet Labs, you need to believe it can turn its growing satellite and AI platform into higher value, recurring solution contracts without overstretching its balance sheet. The Pelican first light milestone and the Czech agriculture deal support that solutions story, but do not fundamentally change the key near term catalyst, which is converting a strong government and sovereign pipeline into cash flow, or the biggest risk around ongoing losses and the need to fund capital intensive satellite programs.

The Czech Republic’s 2 year, 7 figure agriculture contract is especially relevant here because it shows Planet selling packaged imagery plus AI analytics, not just raw data. That fits with the consensus catalyst that higher value “solutions” for governments and enterprises could lift margins and revenue quality, while also testing whether Planet’s expanding Pelican fleet and AI tools can scale efficiently without driving up costs faster than revenue.

But despite these encouraging wins, investors should also be aware that the capital required for Pelican and future fleets could still...

Read the full narrative on Planet Labs PBC (it's free!)

Planet Labs PBC’s narrative projects $744.3 million revenue and $54.6 million earnings by 2029. This requires 34.2% yearly revenue growth and a $301.5 million earnings increase from -$246.9 million today.

Uncover how Planet Labs PBC's forecasts yield a $36.33 fair value, a 13% downside to its current price.

Exploring Other Perspectives

While the baseline view focuses on steady solution driven growth, the most optimistic analysts expect about 40 percent annual revenue growth and a swing to slightly positive earnings, yet they also flag contract concentration risks that could look different in light of Pelican’s progress and the new European agriculture work.

Explore 12 other fair value estimates on Planet Labs PBC - why the stock might be worth as much as $40.00!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Planet Labs PBC research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Planet Labs PBC research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Planet Labs PBC's overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com